Long-term outcomes of pediatric kidney transplant recipients with a pretransplant malignancy

Oscar K. Serrano, Alexis Gannon, Ayokunle S. Olowofela, Apoorva Reddy, Danielle Berglund, Arthur J. Matas

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


A childhood malignancy can rarely progress to ESRD requiring a KT. To date, few reports describe long-term outcomes of pediatric KT recipients with a pretransplant malignancy. Between 1963 and 2015, 884 pediatric (age: 0-17 years old) recipients received 1055 KTs at our institution. KT outcomes were analyzed in children with a pretransplant malignancy. We identified 14 patients who had a pretransplant malignancy prior to KT; the majority were <10 years old at the time of KT. Ten (71%) patients received their grafts from living donors, the majority of which were related to the recipient. Wilms' tumor was the dominant type of pretransplant malignancy, seen in 50% of patients. The other pretransplant malignancy types were EBV-positive lymphoproliferative disorders, non-EBV-positive lymphoma, leukemia, neuroblastoma, soft-tissue sarcoma, and ovarian cancer. Ten of the 14 patients received chemotherapy as part of their pretransplant malignancy treatment. Graft survival at 1, 3, and 5 years was 93%, 83%, and 72%, respectively. Patient survival at 1, 5, and 10 years was 100%, 91%, and 83%, respectively. Six (40%) patients suffered AR following KT; half of them had their first episode of AR within 1 month of KT. Our single-center experience demonstrates that pediatric KT recipients with a previously treated pretransplant malignancy did not exhibit worse outcomes than other pediatric KT patients.

Original languageEnglish (US)
Article numbere13557
JournalPediatric transplantation
Issue number7
StatePublished - Nov 1 2019


  • immunosuppression
  • nephrotoxicity
  • pediatric kidney transplantation
  • pretransplant malignancy

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Long-term outcomes of pediatric kidney transplant recipients with a pretransplant malignancy'. Together they form a unique fingerprint.

Cite this